Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Indaptus Therapeutics reported its Q3 2026 financial results, highlighting a cash and short-term investment position of approximately $30.6 million following a $24 million private placement. The company is shifting its strategic focus toward neurotechnology and neural-network-based devices for sleep-related conditions while significantly reducing R&D expenses by 82% year-over-year.
“Our strategic objective is to position Indaptus for its next phase of growth by actively pursuing innovative opportunities with significant long-term potential and expanding the Company’s strategic focus into promising areas of medical innovation. We believe the successful completion of our approximately $24.0 million private placement provides an important foundation to advance this vision, giving us the financial resources and strategic flexibility to explore new opportunities and build long-term shareholder value.”
Junyi Dai, Indaptus Therapeutics’ Chief Executive Officer and Chairman of the Board
“We are particularly excited about the opportunity to explore the potential of an innovative neurotechnology- and neural-network-based device for certain sleep-related conditions. We believe this area represents an intriguing opportunity to investigate novel approaches to addressing unmet needs in sleep-related health. Through early-stage research and preclinical evaluation, we hope to further assess its scientific potential and explore a possible development pathway toward a future FDA submission.”
Junyi Dai, Indaptus Therapeutics’ Chief Executive Officer and Chairman of the Board
Jinyi Guo, CEO, sold 200,000 shares of Luckin Coffee Inc. at $36.44 a share, worth $7.29M in total on Nov 11, 2026. Shares held after the trade: 2,563,000 (-7.2%).
Trinity Capital CEO, President and CIO Kyle Steven Brown Buys $58K of Stock
Kyle Steven Brown, CEO, President and CIO, bought 3,215 shares of Trinity Capital Inc. at $18.04 a share, worth $58K in total on Nov 11, 2026. Shares held after the trade: 654,878 (+0.5%).
WinVest Acquisition Deal Termination with Embed Financial Group Holdings
Winvest Acquisition Corp. mutually agreed to terminate its previously announced business combination agreement with Embed Financial Group Holdings, effective November 9, 2026. As a result of the termination, the planned merger transactions were abandoned and all related ancillary documents were cancelled. The parties have entered into a mutual release of all claims and liabilities related to the transaction.
Ryan J. Smith has transitioned from Chief Operating Officer to Delivery Project Executive as part of an internal restructuring of Azure Energy. As a result of this change in responsibilities, he is no longer considered an executive officer, and the company does not currently intend to appoint a successor COO.
First Advantage Director Slta V (Gp) L.L.C. Sells $324M of Stock
Slta V (Gp) L.L.C., Director, sold 15,000,000 shares of First Advantage Corp at $21.60 a share, worth $324M in total on Nov 12, 2026. Shares held after the trade: 52,846,632 (-22.1%).
Enova International Director Linda Johnson Rice Sells $204K of Stock
Linda Johnson Rice, Director, sold 1,200 shares of Enova International, Inc. at $170.00 a share, worth $204K in total on Nov 11, 2026. Shares held after the trade: 5,077 (-19.1%).
Beta Technologies COO Sean Donovan Sells $651K of Stock
Sean Donovan, COO, sold 23,167 shares of Beta Technologies, Inc. at $28.01 to $28.38 a share (average $28.12) in 2 transactions, worth $651K in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 240,972 (-2.7%).
Intercontinental Exchange CTO Mayur Kapani Sells $765K of Stock
Mayur Kapani, CTO, sold 4,272 shares of Intercontinental Exchange, Inc. at $176.90 to $180.31 a share (average $179.05) in 4 transactions, worth $765K in total on Nov 11, 2026. Shares held after the trade: 69,480 (-0.8%).
Corcept Therapeutics Director Daniel N. Swisher Jr. Sells $111K of Stock
Daniel N. Swisher Jr., Director, sold 1,500 shares of Corcept Therapeutics Inc at $74.07 a share, worth $111K in total on Nov 10, 2026. Shares held after the trade: 0 (-100.0%).
IRulya Therapeutics (formerly Quince Therapeutics) reported Q3 2026 financial results and provided a corporate update following its recent rebranding and leadership appointments. The company ended the quarter with $105.2 million in cash, which is expected to fund operations through 2028, supporting Phase 2 clinical readouts for its lead candidate LAM-001 in pulmonary diseases.
Term
Q3 2026
“This has been a transformative quarter for our company as we relaunched with a new name and sharpened focus on LAM-001, a potentially first in class inhaled formulation of rapamycin for serious pulmonary diseases. By targeting the mTOR pathway directly in the lungs, LAM-001 holds promise as a potentially disease modifying intervention designed to simultaneously minimize systemic exposure and side effects in these conditions. With a cash runway sufficient to deliver Phase 2 clinical results from multiple indications, we believe IRulya is in a great position to realize LAM-001’s potential.”
Brigette Roberts, M.D., Chief Executive Officer of IRulya Therapeutics
TPG Private Equity Opportunities, L.P. is an emerging growth company that invests primarily through the T-POP US Aggregator (CYM), L.P. As of November 10, 2026, the fund had approximately 62.3 million limited partnership units outstanding across seven different classes, including Class I and Class R-S as the largest components.
Four Corners Property Trust President and CEO William H. Lenehan Buys $150K of Stock
William H. Lenehan, President and CEO, bought 6,468 shares of Four Corners Property Trust, Inc. at $23.19 a share, worth $150K in total on Nov 13, 2026. Shares held after the trade: 796,325 (+0.8%).
Genius Sports Chief Commercial Officer Jack Davison Sells $184K of Stock
Jack Davison, Chief Commercial Officer, sold 30,000 shares of Genius Sports Ltd at $6.14 a share, worth $184K in total on Nov 12, 2026. Shares held after the trade: 1,999,706 (-1.5%).
Evernorth Holdings Inc. reported its third-quarter 2026 financial results, highlighting continued growth in its pharmacy benefit management and specialty pharmacy segments. The filing indicates a focus on expanding specialty pharmacy capabilities and managing medical cost trends effectively while maintaining stable full-year guidance.
Boston Omaha Corporation's Board of Directors has voted to significantly increase its share repurchase program from $30 million to $85 million. The program allows for repurchases of Class A common stock through open market or private transactions and is set to expire on December 31, 2027. The company intends to fund the buybacks using available cash and cash equivalents.
For the quarter ended September 30, 2026, eGain reported total revenue of $21.9 million, a decrease from $23.5 million in the prior year, primarily driven by lower SaaS and professional services revenue. Net income declined to $1.55 million ($0.06 per diluted share) compared to $2.82 million ($0.10 per diluted share) in the same period last year. The company continued its share repurchase program, spending $3.6 million to buy back 644,000 shares during the quarter.
NIQ Global Intelligence reported Q3 2026 financial results, achieving positive GAAP EPS for the first time since its IPO with net income of $35.8 million. The company exceeded guidance across all key metrics, raised its full-year 2026 outlook, and announced a new $150 million share repurchase authorization after reaching its net leverage target ahead of schedule.
“Q3 was a milestone quarter — we exceeded the top end of our guidance across all key metrics for the sixth consecutive quarter, delivered positive GAAP earnings per share for the first time since our IPO, and reached our net leverage milestone a quarter ahead of plan.”
Jim Peck, Executive Chairman and Chief Executive Officer
Core University Living Real Estate Income Trust commenced operations in July 2026, acquiring an initial portfolio of four student housing properties for approximately $300.5 million. For the period from formation through September 30, 2026, the company reported a net loss of $2.8 million on rental revenues of $6.3 million, primarily due to depreciation, interest expense, and general and administrative costs.
PharmaCyte Biotech implemented a 1-for-19 reverse stock split of its common stock effective November 12, 2026. The split consolidated approximately 10.8 million outstanding shares into roughly 0.57 million shares to increase the per-share trading price. The action is intended to help the company regain compliance with the Nasdaq minimum bid price requirement for continued listing.
As of September 30, 2026, the Hashdex Nasdaq CME Crypto Index ETF reported net assets of $498.3 million, a significant increase from $121.3 million at the end of 2025. The Trust's portfolio is heavily weighted in Bitcoin (73.79%) and Ethereum (11.98%), and it recently transitioned its reference index to the Nasdaq CME Crypto Settlement Price Index in January 2026.
Icu Medical Insider Elisha W. Finney Sells $316K of Stock
Elisha W. Finney sold 1,765 shares of Icu Medical Inc at $179.00 a share, worth $316K in total between Nov 12, 2026 and Nov 13, 2026. Shares held after the trade: 4,871 (-25.9%).
Arxis Insider Ross Bradley Sealfon Sells $783K of Stock
Ross Bradley Sealfon sold 15,000 shares of Arxis, Inc. at $51.44 to $53.03 a share (average $52.23) in 3 transactions, worth $783K in total on Nov 11, 2026. Shares held after the trade: 1,087,807 (-0.4%).
Altimmune CFO Gregory L. Weaver Buys $16.2K of Stock
Gregory L. Weaver, CFO, bought 10,000 shares of Altimmune, Inc. at $1.62 a share, worth $16.2K in total on Nov 13, 2026. Shares held after the trade: 73,005 (+15.9%).
Cavco Industries President,Manufactured Housing Brian R. Cira Sells $1.59M of Stock
Brian R. Cira, President,Manufactured Housing, sold 2,382 shares of Cavco Industries, Inc. at $666.91 a share, worth $1.59M in total on Nov 10, 2026. Shares held after the trade: 1,908 (-55.5%).
Altimmune Director Wayne Pisano Buys $16.4K of Stock
Wayne Pisano, Director, bought 10,000 shares of Altimmune, Inc. at $1.64 a share, worth $16.4K in total on Nov 13, 2026. Shares held after the trade: 58,800 (+20.5%).
Aldeyra Therapeutics Director Richard Douglas Buys $129K of Stock
Richard Douglas, Director, bought 200,000 shares of Aldeyra Therapeutics, Inc. at $0.6445 a share, worth $129K in total on Nov 11, 2026. Shares held after the trade: 395,000 (+102.6%).
Cinemark Holdings, Inc. declared a quarterly cash dividend of $0.09 per share of common stock. The dividend is scheduled to be paid on December 9, 2026, to stockholders of record as of November 25, 2026.
Ares Industrial Real Estate Income Trust Business Update
Ares Industrial Real Estate Income Trust reported its monthly Net Asset Value (NAV) as of October 31, 2026, with an Aggregate Fund NAV of approximately $5.31 billion. The transaction price for December 1, 2026, will be based on this updated NAV per share calculation. The filing also details the company's total investment portfolio of $10.36 billion, which includes industrial properties, joint ventures, and real estate debt.
Altimmune President and CEO Jerome Benedict Durso Buys $49.7K of Stock
Jerome Benedict Durso, President and CEO, bought 30,700 shares of Altimmune, Inc. at $1.62 a share, worth $49.7K in total on Nov 13, 2026. Shares held after the trade: 93,200 (+49.1%).